AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tripelennamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2762 | 91-81-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat ASTHMA; HAY FEVER; URTICARIA; and RHINITIS; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.15 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 2.84 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.435 | Moderate | 0.74 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.759 | Moderate | 0.74 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 32.285 | 10^-6 cm/s | Moderate | 0.74 |
| dh-clint | Dog hepatocyte intrinsic clearance | 111.173 | uL/min/10^6 cells | Moderate | 0.74 |
| dppb | Dog plasma protein binding (% unbound) | 61.800 | % | Moderate | 0.74 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 67.170 | % | Moderate | 0.74 |
| herg | hERG pIC50 | 5.267 | pIC50 | Moderate | 0.74 |
| hh-clint | Human hepatocyte intrinsic clearance | 13.868 | uL/min/10^6 cells | Moderate | 0.74 |
| hlm-clint | Human liver microsomal intrinsic clearance | 29.376 | uL/min/mg protein | Moderate | 0.74 |
| hppb | Human plasma protein binding (% unbound) | 53.510 | % | Moderate | 0.74 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK12,MAPK7,MET,MTOR,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK | 35 | |||
| kinase-selectivity-class | AXL,BRAF,ERBB2 | 3 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.303 | Moderate | 0.74 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 266.073 | Moderate | 0.74 | |
| mppb | Mouse plasma protein binding (% unbound) | 64.800 | Moderate | 0.74 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.711 | Moderate | 0.74 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 77.810 | % | Moderate | 0.74 |
| rh-clint | Rat hepatocyte intrinsic clearance | 294.442 | uL/min/10^6 cells | Moderate | 0.74 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 81.670 | % | Moderate | 0.74 |
| rppb | Rat plasma protein binding (% unbound) | 65.740 | % | Moderate | 0.74 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 950.605 | uM | Moderate | 0.74 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 19, 1948 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D04AA04 | DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Antihistamines for topical use |
| ATC | R06AC04 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted ethylene diamines |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006634 | Histamine H1 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018926 | Anti-Allergic Agents |
Related Drugs by ATC class:
D04AA Antihistamines for topical use 13 drugs
R06AC Substituted ethylene diamines 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dermatographic urticaria | indication | 7632005 | DOID:743 |
| Vasomotor rhinitis | indication | 8229003 | DOID:4730 |
| Allergic rhinitis | indication | 61582004 | |
| Nasal discharge | indication | 64531003 | |
| Nasal congestion | indication | 68235000 | |
| Sneezing | indication | 76067001 | |
| Urticaria | indication | 126485001 | |
| Itching of skin | indication | 418363000 | |
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Anaphylaxis Adjunct | indication | ||
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Chronic idiopathic constipation | contraindication | 82934008 | |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Antihistaminic therapy | Indication |
| Cattle | Antihistaminic therapy | Indication |
| Dogs | Antihistaminic therapy | Indication |
| Horses | Antihistaminic therapy | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| RE-COVR | Kinetic Technologies LLC | 1 |
| Tripelennamine Hydrochloride Injection | Huvepharma EOOD | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.62 | Basic |
| pKa2 | 4.33 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | GPCR | ANTAGONIST | IC50 | 7.40 | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019963 | VUID |
| N0000148048 | NUI |
| D02091 | KEGG_DRUG |
| 4018394 | VANDF |
| 4018395 | VANDF |
| 4019963 | VANDF |
| C0041090 | UMLSCUI |
| CHEBI:9741 | CHEBI |
| CHEMBL1241 | ChEMBL_ID |
| CHEMBL1200446 | ChEMBL_ID |
| CHEMBL151676 | ChEMBL_ID |
| DB00792 | DRUGBANK_ID |
| CHEMBL1200769 | ChEMBL_ID |
| D014309 | MESH_DESCRIPTOR_UI |
| 5587 | PUBCHEM_CID |
| 7318 | IUPHAR_LIGAND_ID |
| 1548 | INN_ID |
| 6138-56-3 | SECONDARY_CAS_RN |
| 154-69-8 | SECONDARY_CAS_RN |
| 3C5ORO99TY | UNII |
| 10847 | RXNORM |
| 3076 | MMSL |
| 5638 | MMSL |
| d00781 | MMSL |
| 003374 | NDDF |
| 003375 | NDDF |
| 003376 | NDDF |
| 25014009 | SNOMEDCT_US |
| 373475006 | SNOMEDCT_US |
| 53405009 | SNOMEDCT_US |
| 3C5ORO99TY | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| PBZ OTC | HUMAN OTC DRUG LABEL | 1 | 69993-151 | CREAM | 1 g | TOPICAL | OTC Monograph Drug | 11 sections |
| Blue-Emu Thrive Pain Relief Cream | HUMAN OTC DRUG LABEL | 1 | 69993-600 | CREAM | 0.50 g | TOPICAL | OTC Monograph Drug | 12 sections |
| Blue-Emu THRIVE Cooling | HUMAN OTC DRUG LABEL | 1 | 69993-650 | CREAM | 0.50 g | TOPICAL | OTC Monograph Drug | 11 sections |